Wnt Signaling Behaves as a "Master Regulator" in the Osteogenic and Adipogenic Commitment of Human Amniotic Fluid Mesenchymal Stem Cells

Stem Cell Reviews and Reports

Volumn 9, Issue 5, 2013, Pages 642-654

  D'Alimonte, Iolanda ^a,b   Lannutti, Angela ^a,b   Pipino, Caterina ^a,b   Di Tomo, Pamela ^a,b   Pierdomenico, Laura ^a,b   Cianci, Eleonora ^a,b   Antonucci, Ivana ^a,b   Marchisio, Marco ^a,b   Romano, Mario ^a,b   Stuppia, Liborio ^a,b   Caciagli, Francesco ^a   Pandolfi, Assunta ^a,b   Ciccarelli, Renata ^a,b,c  

^a UNIVERSITY OF CHIETI   (Italy)

^b Stem TeCh Group   (Italy)

^c Department of Experimental and Clinical Sciences Section of Pharmacology   (Italy)

Author keywords

Human amniotic fluids; Mesenchymal stem cells; Osteogenic adipogenic differentiation; Wnt signaling

Indexed keywords

ALKALINE PHOSPHATASE; BETA CATENIN; DISHEVELLED PROTEINS; DKK1 PROTEIN, HUMAN; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE, FAD DEPENDENT; GLYCEROL-3-PHOSPHATE DEHYDROGENASE, FAD-DEPENDENT; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOPROTEIN; RUNX2 PROTEIN, HUMAN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSCRIPTION FACTOR RUNX2;

ADIPOGENESIS; AMNION FLUID; ARTICLE; BONE DEVELOPMENT; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STROMA CELL; METABOLISM; OSTEOBLAST; PHOSPHORYLATION; PHYSIOLOGY; PREGNANCY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WNT SIGNALING PATHWAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADIPOGENESIS; ALKALINE PHOSPHATASE; AMNIOTIC FLUID; BETA CATENIN; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FATTY ACID-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GLYCEROLPHOSPHATE DEHYDROGENASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; OSTEOGENESIS; PHOSPHOPROTEINS; PHOSPHORYLATION; PPAR GAMMA; PREGNANCY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; WNT SIGNALING PATHWAY;

EID: 84884817069     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-013-9436-5     Document Type: Article

References (67)

1. Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., Schwartz, R. E., Keene, C. D., Ortiz-Gonzalez, X. R., et al. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature, 418(6893), 41-49.
2. Baksh, D., Song, L., & Tuan, R. S. (2004). Adult mesenchymal stem cells: characterization, differentiation and application in cell therapy. Molecular Medicine, 8, 301-316.
3. Shekkeris, A. S., Jaiswal, P. K., & Khan, W. S. (2012). Clinical applications of mesenchymal stem cells in the treatment of fracture non-union and bone defects. Current Stem Cell Research & Therapy, 7(2), 127-133.
4. Khojasteh, A., Behnia, H., Dashti, S. G., & Stevens, M. (2012). Current trends in mesenchymal stem cell application in bone augmentation: a review of the literature. Journal of Oral and Maxillofacial Surgery, 70(4), 972-982.
5. Jones, E., & Yang, X. (2011). Mesenchymal stem cells and bone regeneration: current status. Injury, 42(6), 562-568.
6. Wang, S., Qu, X., & Zhao, R. C. (2012). Clinical applications of mesenchymal stem cells. Journal of Hematology & Oncology, 5, 19.
7. Tokalov, S. V., Grüner, S., Schindler, S., Wolf, G., Baumann, M., & Abolmaali, N. (2007). Age-related changes in the frequency of mesenchymal stem cells in the bone marrow of rats. Stem Cells and Development, 16(3), 439-446.
8. Sessarego, N., Parodi, A., Podestà, M., Benvenuto, F., Mogni, M., Raviolo, V., et al. (2008). Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. Haematologica, 93(3), 339-346.
9. You, Q., Tong, X., Guan, Y., Zhang, D., Huang, M., Zhang, Y., et al. (2009). The biological characteristics of human third trimester amniotic fluid stem cells. Journal of International Medicine Research, 37(1), 105-112.
10. Miranda-Sayago, J. M., Fernandez-Arcas, N., Benito, C., Reyes-Engel, A., Carrera, J., & Alonso, A. (2011). Lifespan of human amniotic fluid-derived multipotent mesenchymal stromal cells. Cytotherapy, 13, 572-581.
11. Ditadi, A., de Coppi, P., Picone, O., Gautreau, L., Smati, R., Six, E., et al. (2009). Human and murine amniotic fluid c-Kit+Lin- cells display hematopoietic activity. Blood, 113(17), 3953-3960.
12. Moschidou, D., Mukherjee, S., Blundell, M. P., Drews, K., Jones, G. N., Abdulrazzak, H., et al. (2012). Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach. Molecular Therapy, 20(10), 1953-1967.
13. Roubelakis, M. G., Trohatou, O., & Anagnou, N. P. (2012). Amniotic fluid and amniotic membrane stem cells: marker discovery. Stem Cells International, 2012, 107836.
14. Zheng, Y. B., Gao, Z. L., Xie, C., Zhu, H. P., Peng, L., Chen, J. H., et al. (2008). Characterization and hepatogenic differentiation of mesenchymal stem cells from human amniotic fluid and human bone marrow: a comparative study. Cell Biology International, 32(11), 1439-1448.
15. Kang, N. H., Hwang, K. A., Kim, S. U., Kim, Y. B., Hyun, S. H., Jeung, E. B., et al. (2012). Potential antitumor therapeutic strategies of human amniotic membrane and amniotic fluid-derived stem cells. Cancer Gene Therapy, 19(8), 517-522.
16. Joo, S., Ko, I. K., Atala, A., Yoo, J. J., & Lee, S. J. (2012). Amniotic fluid-derived stem cells in regenerative medicine research. Archives of Pharmacological Research, 35(2), 271-280.
17. De Coppi, P., Bartsch, G., Jr., Siddiqui, M. M., Xu, T., Santos, C. C., Perin, L., et al. (2007). Isolation of amniotic stem cell lines with potential for therapy. Nature Biotechnology, 25, 100-106.
18. Phermthai, T., Suksompong, S., Tirawanchai, N., Issaragrisil, S., Julavijitphong, S., Wichitwiengrat, S., et al. (2012) Epigenetic analysis and suitability of amniotic fluid stem cells for research and therapeutic purposes. Stem Cells Development Dec 18 [Epub ahead of print].
19. Moschidou, D., Mukherjee, S., Blundell, M. P., Jones, G. N., Atala, A. J., Thrasher, A. J., et al. (2013). Human mid-trimester amniotic fluid stem cells cultured under embryonic stem cell conditions with valproic acid acquire pluripotent characteristics. Stem Cells and Development, 22(3), 444-458.
20. Abdulrazzak, H., De Coppi, P., & Guillot, P. V. (2012) Therapeutic potential of amniotic fluid stem cells. Current Stem Cell Research & Therapy Nov. 2012 [Epub ahead of print].
21. Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143-147.
22. Caplan, A. I., & Bruder, S. P. (2001). Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends in Molecular Medicine, 7(6), 259-264.
23. Bhattacharyya, S., Kumar, A., & Lal Khanduja, K. (2012). The voyage of stem cell toward terminal differentiation: a brief overview. Acta Biochimica et Biophysica Sinica (Shanghai), 4(6), 463-475.
24. Rao, T. P., & Kühl, M. (2010). An updated overview on Wnt signaling pathways: a prelude for more. Circulation Research, 106(12), 1798-1806.
25. Yavropoulou, M. P., & Yovos, J. G. (2007). The role of the Wnt signaling pathway in osteoblast commitment and differentiation. Hormones, 6(4), 279-294.
26. Goldring, S. R., & Goldring, M. B. (2007). Eating bone or adding it: the Wnt pathway decides. Nature Medicine, 13(2), 133-134.
27. Macsai, C. E., Foster, B. K., & Xian, C. J. (2008). Role of Wnt signaling in bone growth, remodeling skeletal disorders and fracture repair. Journal of Cellular Physiology, 215, 578-587.
28. Christodoulides, C., Lagathu, C., Sethi, J. K., & Vidal-Plug, A. (2009). Adipogenesis and Wnt signaling. Trends in Endocrinology and Metabolism, 220(1), 16-24.
29. de Boer, J., Siddappa, R., Gaspar, C., van Apeldoorn, A., Fodde, R., & van Blitterswijk, C. (2004). Wnt signaling inhibits osteogenic differentiation of human mesenchymal stem cells. Bone, 34(5), 818-826.
30. Cho, H. H., Kim, Y. J., Kim, S. J., Kim, J. H., Bae, Y. C., Ba, B., et al. (2006). Endogenous Wnt signaling promotes proliferation and suppresses osteogenic differentiation in human adipose derived stromal cells. Tissue Engineering, 12(1), 111-121.
31. Scheller, E. L., Chang, J., & Wang, C. Y. (2008). Wnt/β-catenin inhibits dental pulp stem cell differentiation. Journal of Dental Research, 87(2), 126-130.
32. Liu, G., Vijayakumar, S., Grumolato, L., Arroyave, R., Qiao, H., Akiri, G., et al. (2009). Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells. The Journal of Cell Biology, 185(1), 67-75.
33. Tang, N., Song, W. X., Luo, J., Luo, X., Chen, J., Sharff, K. A., et al. (2009). BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signalling. Journal of Cellular and Molecular Medicine, 13(8B), 2448-2464.
34. Lanuti, P., Fuhrmann, S., Lachmann, R., Marchisio, M., Miscia, S., & Kern, F. (2009). Simultaneous characterization of phospho-proteins and cell cycle in activated T cell subsets. International Journal of Immunopathology and Pharmacology, 22, 689-698.
35. Lanuti, P., Santilli, F., Marchisio, M., Pierdomenico, L., Vitacolonna, E., Santavenere, E., et al. (2012). A novel flow cytometric approach to distinguish circulating endothelial cells from endothelial microparticles: relevance for the evaluation of endothelial dysfunction. Journal of Immunological Methods, 380(1-2), 16-22.
36. Lanuti, P., Ciccocioppo, F., Bonanni, L., Marchisio, M., Lachmann, R., Tabet, N., et al. (2012). Amyloid-specific T-cells differentiate Alzheimer's disease from Lewy body dementia. Neurobiology of Aging, 33(11), 2599-2611.
37. D'Alimonte, I., Nargi, E., Mastrangelo, F., Falco, G., Lanuti, P., Marchisio, M., et al. (2011). Vascular endothelial growth factor enhances in vitro proliferation and osteogenic differentiation of human dental pulp stem cells. Journal of Biological Regulators and Homeostatic Agents, 25(1), 57-69.
38. Gregory, C. A., Gunn, W. G., Peister, A., & Prockop, D. J. (2004). An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Analytical Biochemistry, 329, 77-84.
39. Laflamme, C., Curt, S., & Rouabhia, M. (2010). Epidermal growth factor and bone morphogenetic proteins upregulate osteoblast proliferation and osteoblastic markers and inhibit bone nodule formation. Archives of Oral Biology, 55, 689-701.
40. Hajra, A. K., Larkins, L. K., Das, A. K., Hemati, N., Erickson, R. L., & MacDougald, O. A. (2000). Induction of the peroxisomal glycerolipid-synthesizing enzymes during differentiation of 3T3-L1 adipocytes. Role in triacylglycerol synthesis. Journal of Biological Chemistry, 275(13), 9441-9446.
41. 1 adenosine receptor activation. Neuroscience Letters, 418(1), 66-71.
42. Tetè, S., Nargi, E., Mastrangelo, F., Zizzari, V., D'Apolito, G., Traini, T., et al. (2008). Changes in matrix extracellular phosphoglycoprotein expression before and during in vitro osteogenic differentiation of human dental papilla mesenchymal cells. International Journal of Immunopathology and Pharmacology, 21(2), 309-318.
43. Sulpizio, M., Falone, S., Amicarelli, F., Marchisio, M., Di Giuseppe, F., Eleuterio, E., et al. (2011). Molecular basis underlying the biological effects elicited by extremely low-frequency magnetic field (ELF-MF) on neuroblastoma cells. Journal of Cell Biochemistry, 112(12), 3797-3806.
44. Glinka, A., Wu, W., Delius, H., Monaghan, A. P., Blumenstock, C., & Niehrs, C. (1998). Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature, 391(6665), 357-362.
45. Fedi, P., Bafico, A., Nieto Soria, A., Burgess, W. H., Miki, T., Bottaro, D. P., et al. (1999). Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. Journal of Biological Chemistry, 274(27), 19465-19472.
46. Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8(4), 315-317.
47. Rosner, M., Dolznig, H., Schipany, K., Mikula, M., Brandau, O., & Hengstschläger, M. (2011). Human amniotic fluid stem cells as a model for functional studies of genes involved in human genetic diseases or oncogenesis. Oncotarget, 2(9), 705-712.
48. Antonucci, I., Stuppia, L., Kaneko, Y., Yu, S., Tajiri, N., Bae, E. C., et al. (2011). Amniotic fluid as a rich source of mesenchymal stromal cells for transplantation therapy. Cell Transplantation, 20(6), 789-795.
49. Arnhold, S., Glüer, S., Hartmann, K., Raabe, O., Addicks, K., Wenisch, S., et al. (2011). Amniotic-fluid stem cells: growth dynamics and differentiation potential after a CD117-based selection procedure. Stem Cells International, 2011, 715341.
50. Moorefiled, E. C., McKee, E. E., Solchaga, L., Orlando, G., Yoo, J. J., Walker, S., et al. (2011). Cloned, CD117 selected human amniotic fluid stem cells are capable of modulating the immune response. Plos One, 6(10), e26535.
51. Wagner, W., Wein, F., Seckinger, A., Frankhauser, M., Wirkner, U., Krause, U., et al. (2005). Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Experimental Hematology, 33, 1402-1416.
52. Poloni, A., Maurizi, G., Babini, L., Serrani, F., Berardinelli, E., Mancini, S., et al. (2011). Human mesenchymal stem cells from chorionic villi and amniotic fluid are not susceptible to transformation after extensive in vitro expansion. Cell Transplantation, 20(5), 643-654.
53. Chen, Q., Xiao, P., Chen, J. N., Cai, J. Y., Cai, X. F., Ding, H., et al. (2010). AFM studies of cellular mechanics during osteogenic differentiation of human amniotic fluid-derived stem cells. Analytical Sciences, 26(10), 1033-1037.
54. Bai, J., Wang, Y., Liu, L., Chen, J., Yang, W., Gao, L., et al. (2012). Human amniotic fluid-derived c-kit(+) and c-kit(-) stem cells: growth characteristics and some differentiation potential capacities comparison. Cytotechnology, 64(5), 577-589.
55. Komori, T. (2010). Regulation of bone development and extracellular matrix protein genes by RUNX2. Cellular Tissue Research, 339, 189-195.
56. Koch, H., Jadlowiec, J. A., & Campbell, P. G. (2005). Insulin-like growth factor-I induces early osteoblast bene expression in human mesenchymal stem cells. Stem Cells and Development, 14(6), 621-631.
57. Costa, M. A., Barbosa, A., Neto, E., Sá-e-Sousa, A., Freitas, R., Neves, J. M., et al. (2011). On the role of subtype selective adenosine receptor agonists during proliferation and osteogenic differentiation of human primary bone marrow stromal cells. Journal of Cellular Physiology, 226, 1353-1366.
58. Yang-Snyder, J., Miller, J. R., Brown, J. D., Lai, C. J., & Moon, R. T. (1996). A frizzled homolog functions in a vertebrate Wnt signaling pathway. Current Biology, 6(10), 1302-1306.
59. Gumbiner, B. M. (1995). Signal transduction of beta-catenin. Current Opinion in Cell Biology, 7(5), 634-640.
60. Day, T. F., Guo, X., Garrett-Beal, L., & Yang, Y. (2005). Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Developmental Cell, 8, 739-750.
61. Glass, D. A., 2nd, Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., et al. (2005). Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Developmental Cell, 8, 751-764.
62. Kugimiya, F., Kawaguchi, H., Ohba, S., Kawamura, N., Hirata, M., Chikuda, H., et al. (2007). GSK-3beta controls osteogenesis through regulating Runx2 activity. PLoS One, 2(9), e837.
63. Ross, S. E., Hemati, N., Longo, K. A., Bennett, C. N., Lucas, P. C., Erickson, R. L., et al. (2000). Inhibition of adipogenesis by Wnt signaling. Science, 289, 950-953.
64. Takada, I., Kouzmenko, A. P., & Kato, S. (2009). Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nature Reviews. Rheumatology, 55(8), 442-447.
65. Farmer, S. R. (2005). Regulation of PPARgamma activity during adipogenesis. International Journal of Obesity (London), 29(Suppl 1), S13-S16.
66. Zaragosi, L. E., Wdziekonski, B., Fontaine, C., Villageois, P., Peraldi, P., & Dani, C. (2008). Effects of GSK3 inhibitors on in vitro expansion and differentiation of human adipose-derived stem cells into adipocytes. BMC Cell Biology, 9.
67. Forde, J. E., & Dale, T. C. (2007). Glycogen synthase kinase 3: a key regulator of cellular fate. Cellular and Molecular Life Sciences, 64(15), 1930-1944.